Analyse automatisée des liquides de ponction et des liquides céphalorachidiens: Evaluation du Sysmex XE-5000
HO, Thi Thanh Giang ; KEUTGENS, Aurore ; HUWART, Aline et al
in Immuno-Analyse & Biologie Spécialisée [=IBS] (2011), 26
Le mode d’analyse des liquides de ponction du Sysmex XE-5000 a été évalué sur 159 liquides de ponction, dont 60 liquides céphalorachidiens. La numération érythrocytaire et leucocytaire a été comparée aux ... [more ▼]
Le mode d’analyse des liquides de ponction du Sysmex XE-5000 a été évalué sur 159 liquides de ponction, dont 60 liquides céphalorachidiens. La numération érythrocytaire et leucocytaire a été comparée aux comptages réalisés en microscopie en chambre de Fuchs-Rosenthal. La différentiation des cellules monucléées et polynucléées par le XE-5000 a été comparée à la formule manuelle obtenue sur lames de cytocentrifugation. Une bonne corrélation a été obtenue entre le XE-5000 et la technique manuelle avec des coefficients de corrélation supérieurs à 0,8 pour la numération des érythrocytes et des leucocytes ainsi que pour la différenciation leucocytaire pour la plupart des liquides de ponction. La limite de sensibilité fonctionnelle (c’est-à-dire une précision intra-série supérieure à 20 %) a été atteinte pour des numérations érythrocytaires inférieures à 400/ L et leucocytaires inférieures à 30/ L. La contamination inter-échantillons est négligeable et la linéarité est satisfaisante jusqu’à 400 érythrocytes/ L et 30 leucocytes/ L. Ces résultats montrent que l’analyse automatisée des liquides de ponction par le XE-5000 est une alternative acceptable à la technique microscopique de référence aussi bien pour la numération érythrocytaire et leucocytaire que pour la différenciation des cellules polymorphonucléées et mononucléées pour la majorité des liquides de ponction y compris les liquides céphalorachidiens. The body fluid mode on the Sysmex XE-5000 automated hematology analyzer was evaluated on 99 body fluids and 60 cerebrospinal fluids. Erythrocyte and leukocyte numeration was compared to microscopic counts on Fuchs-Rosenthal chambers. Differentiation of mononuclear (MN) and polymorphonuclear (PMN) cells on the XE-5000 was compared to manual differential on cytospin slides. A good agreement was found between the XE-5000 and the manual method with correlation coefficients more than 0.8 for erythrocyte counts, leukocyte counts and leukocyte differentiation in most types of body fluids. The functional sensitivity limit (i.e., within run precision more than 20%) was reached for red blood cell counts more than 400/ L and white blood cell counts more than 30/ L. Carry over was negligible and linearity was adequate for as low as 400 erythrocytes/ L and 30 leucocytes/ L. Our results demonstrate that the automated body fluid analysis on the XE-5000 is an acceptable alternative to the microscopic reference method for erythrocyte and leukocyte numeration as well as MN and PMN differential for most body fluids including cerebrospinal fluids. [less ▲]Detailed reference viewed: 56 (13 ULg)
CHIC cells: a novel ALK+ cell line derived from a relapsed anaplastic large cell lymphoma
Thielen, Caroline ; Bisig, Bettina ; Gofflot, Stéphanie et al
in British Journal of Haematology (2011), 152
Since the initial description of anaplastic large cell lymphoma (ALCL) as a proliferation of large CD30+ lymphoid cells, the morphological spectrum of ALCL positive for anaplastic lymphoma kinase (ALCL ... [more ▼]
Since the initial description of anaplastic large cell lymphoma (ALCL) as a proliferation of large CD30+ lymphoid cells, the morphological spectrum of ALCL positive for anaplastic lymphoma kinase (ALCL, ALK+) has expanded, and beyond the common pattern most frequently encountered, several variants have been identified, including the lymphohistiocytic and the small cell patterns (Swerdlow et al, 2008). Only ten ALK+ ALCL cell lines are currently available, and most were derived from tumours demonstrating the common type morphology (Drexler & MacLeod, 2004). We have established a novel cell line (CHIC) from the cerebrospinal fluid of a 32-year-old man with relapsing/refractory ALK+ ALCL with a t(2;5)(p23;q35) translocation whose initial tumour exhibited lymphohistiocytic features. This cell line is now made available to the scientific community. In addition to multiple in vitro applications, the tumourigenic capacity of these cells represents a useful property for in vivo drug testing. [less ▲]Detailed reference viewed: 44 (20 ULg)
Inositide-specific phospholipase c beta1 gene deletion is a rare event in myelodysplastic syndromes.
Herens, Christian ; ; Tassin, Françoise et al
in Leukemia (2006), 20(3), 521-2522-3Detailed reference viewed: 16 (8 ULg)
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Herens, Christian ; Baron, Frédéric ; et al
in Cancer Genetics & Cytogenetics (2003), 147(1), 78-80
Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal ... [more ▼]
Imatinib mesylate (tested as STI571), an abl kinase inhibitor, induces sustained, complete hematologic and cytogenetic responses in chronic myelocytic leukemia (CML) patients; however, emergence of clonal chromosomal aberrations in Philadelphia-negative (Ph-) cells during treatment has been reported. We describe two CML patients in chronic phase who presented with complete cytogenetic responses during imatinib mesylate therapy but developed new clonal chromosomal rearrangements in Ph- cells. The first patient presented with a duplication of chromosome 1, dup(1)(q21q42), and the second showed two new clonal aberrations consisting of inv(1)(q12q32) and del(7)(q22) in the same clone. [less ▲]Detailed reference viewed: 68 (11 ULg)
Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia.
Piron, Maude ; ; Gothot, André et al
in Blood (2001), 97(2), 442-8
Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo ... [more ▼]
Little information is available on the evolution of erythropoiesis after interruption of recombinant human erythropoietin (rHuEpo) therapy. Iron-overloaded rats received 20 daily injections of rHuEpo. During treatment, reticulocytes, soluble transferrin receptor (sTfR), and hematocrit increased progressively. This was accompanied by a substantial expansion of spleen erythropoiesis but a decrease in the bone marrow. Five weeks after treatment, rats developed a significant degree of a regenerative anemia. Erythropoietic activity, as assessed by reticulocytes, sTfR, erythroid cellularity, iron incorporation into heme, and the number of erythroid colonies, was severely depressed 3 weeks after cessation of rHuEpo. This was followed by regeneration of erythroblasts and reticulocytes at weeks 6 to 7 post-Epo, but erythroid progenitors recovered only partially by that time. The anemia was definitely corrected 2 months after cessation of rHuEpo treatment. Serum Epo levels remained elevated for several weeks, but the sensitivity of marrow erythroid precursors to Epo was preserved. No rat antibodies to rHuEpo were detected, and serum from post-Epo animals did not exert any inhibitory activity on erythropoiesis. In conclusion, after cessation of intensive rHuEpo therapy, there was a strong inhibition of erythropoietic activity with secondary anemia followed by late recovery. This was not due to antibodies or other soluble inhibitory factors, a defect in endogenous Epo production, or a loss of sensitivity to Epo. This may rather represent intrinsic erythroid marrow exhaustion, mostly at the level of erythroid progenitors but also at later stages of erythropoiesis. [less ▲]Detailed reference viewed: 32 (7 ULg)
Deletion of the 5'-ABL region: a recurrent anomaly detected by fluorescence in situ hybridization in about 10% of Philadelphia-positive chronic myeloid leukaemia patients.
Herens, Christian ; Tassin, Françoise ; Lemaire, Véronique et al
in British Journal of Haematology (2000), 110(1), 214-6
Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This ... [more ▼]
Inclusion of the BCR-ABL ES probe in routine cytogenetics led to the identification of a subgroup of Philadelphia positive (Ph+) chronic myeloid leukaemia patients characterized by a 5'-ABL deletion. This anomaly was observed in 5/51 cases (9.8%). Cytological and clinical data suggest that the 5'-ABL deletion may be associated with dysplastic features of polymorphonuclear cells and metamyelocytes and a short chronic phase duration. [less ▲]Detailed reference viewed: 25 (6 ULg)
A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
Tassin, Françoise ; Dewé, Walthère ; Schaaf, Nicole et al
in Leukemia & Lymphoma (2000), 36(5-6), 485-96
Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow ... [more ▼]
Marrow dysplasia is a major characteristic of patients with myelodysplastic syndrome (MDS), along with marrow blastosis, cytopenia and cytogenetic anomalies. However, the impact of the degree of marrow dysplasia on survival has not been fully assessed. In this retrospective analysis of 111 patients selected according to the IPSS criteria of MDS diagnosis, the presence or absence of 21 dysplasia characteristics recognizable in bone marrow smears stained by the May-Grunwald-Giemsa method was correlated with patient survival. Using Cox proportional hazards regression analysis, megaloblastosis (MEGALO), neutrophil agranularity (AGRAN) and hypogranularity (HYPOGRAN) were highly significant predictors (p < 0.005), and Pelger-Huet anomaly (PELGHUET) a significant predictor (p = 0.05), of patient survival. The regression analysis yielded a dysplasia-based risk index (DI) where DI = 1.26 MEGALO + 0.82 AGRAN - 1.08 HYPOGRAN + 0.45 PELGHUET. The two subgroups of 60 and 47 patients with DI < or = 0 and > 0 showed highly significant differences in median survivals (2.6 vs 1.1 yrs; p <0.0001). Multivariate analysis further showed that DI offered additional predictive power that was independent of that provided by the IPSS (p=0.002 and 0.001 respectively). Analysis of survival curves stratified for IPSS and DI showed that the additional predictive power offered by inclusion of the DI essentially concerned the IPSS low/INT-1 risk categories. Further stratification for age did not improve survival prediction. The data indicate that a set of 4 dysplasia parameters can offer some prediction for survival of MDS patients in addition to that provided by the IPSS. Further multicenter studies should aim at including some form of evaluation of the degree of dysplasia in prognostic systems. [less ▲]Detailed reference viewed: 42 (7 ULg)
Translocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis.
Herens, Christian ; ; Tassin, Françoise et al
in Cancer Genetics & Cytogenetics (1999), 110(1), 62-4
Translocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly. The comparison with ... [more ▼]
Translocation t(2p;3q) is a rare but recurrent finding in myeloid disorders. We present the first case of primary myelofibrosis with t(2;3)(p21;q26) as the sole chromosomal anomaly. The comparison with the 11 other previously published myeloid-associated t(2p;3q) cases confirms that this nonrandom translocation involves a pluripotent stem cell and is associated with a poor prognosis. [less ▲]Detailed reference viewed: 54 (11 ULg)
Les syndromes myélodysplasiques: syndromes préleucémiques
Tassin, Françoise ; ; Schaaf-Lafontaine, Nicole et al
in Revue Médicale de Liège (1998), 53(6), 357-62
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly ... [more ▼]
The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting dyspoiesis. The predominant in elderly patients are associated with a high risk of progression to acute myelogenous leukemia. The etiology of MDS is unknown in most cases. About 10% of MDSs are secondary. MDS are classified by the French American British (FAB) classification into five subgroups. The incidence of the disorders is difficult to estimate but it seems to be increasing. Clonal cytogenetic aberrations are found in 30 to 50% of de novo MDS. The only currative treatment for MDS is allogeneic bone marrow transplantation. [less ▲]Detailed reference viewed: 84 (6 ULg)
Rétinoïdes et leucémie aigue promyelocytaire. Une révolution thérapeutique
; Tassin, Françoise ; Bours, Vincent et al
in Revue Médicale de Liège (1996), 51(3), 217-23Detailed reference viewed: 44 (2 ULg)